Regenerative medicine startup Juventas Therapeutics is planning to begin enrollment in a phase 2 heart failure clinical trial next quarter.
The Cleveland-based company’s technology, JVS-100, works by recruiting stem cells from the bone marrow to create new blood vessels and prevent ongoing cell death at the site of a patient’s injury.
During the trial, Juventas will deliver its therapeutic via catheters from BioCardia, according to a statement from California-based BioCardia.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In January, Juventas touted the 12-month results of its phase 1 heart failure trial. At 12 months, heart failure patients treated with the company’s stem cell therapy showed “significant” improvements in two key measures: a six-minute distance-walking test and the Minnesota Living with Heart Failure Questionnaire, a patient self-assessment of how heart failure affects daily life.
In addition to the heart failure trial, Juventas has already begun enrollment in a phase 2a trial that will assess the safety and efficacy of JVS-100 in critical limb ischemia patients.
Juventas was founded to commercialize technology developed by cardiologist Dr. Marc Penn, director of research at the Summa Cardiovascular Institute in Akron, Ohio.
